1. INTRODUCTION Prostate cancer (PC) is the second leading cause of cancer death nationwide for men over age 60 years. Currently, there is no scientific consensus on effective strategies to reduce the risk of PC . Additionally, there is no agreement on the effectiveness of screening or that the potential benefits outweigh the risks . Public health agencies are recommending that physicians and patients should reach a decision about screening collaboratively via shared decision making [2-5]. This allows patients to be informed about the benefits and risks of PC screening, treatment and to include their own values and preferences in the process.